10x Genomics, Inc.

NASDAQ:TXG

Medical - Healthcare Information Services

Healthcare
$57.07 +7.75%

+$2.49 today

Market cap
$6.93B
Beta
2.11
P/E (TTM)
-196.0
EPS (TTM)
-$0.18
52W Low $10.48High $35.65

Volume 2.10M

Average 3.06M

TXG Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

10x Genomics, Inc.NASDAQ: TXG

Research & Development · Q3 FY2026 · quarter ended Sep 2026

Research & development declines year over year

Q3 FY2026 research & development of $52.93M fell 7.5% year over year, ahead of the -10.9% change in trailing-twelve-month research & development. Sequentially, it fell 6.8% from the prior quarter. Over 3 fiscal years it compounded at -3.5% a year.

Context

  • Research & development amounted to 37.1% of revenue in FY2025, down 6.2 pp from a year earlier.
  • Research & development increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of -7.5% holds above the trailing-twelve-month pace of -10.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$52.93M-6.8% QoQ
Last fiscal yearDec 2025
$238.63M-9.8% YoY
LTMSep 2026
$222.54M-10.9% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-7.5%——
1 year-9.8%——
3-year CAGR-3.5%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
238.63M USD
Year-over-year change
-9.8%
4-year CAGR
+3.0%

Research & Development vs competitors

How TXG compares with its peers on the latest reported figures

  • TXG's LTM Sep 2026 research & development of $222.54M is the 4th highest of the 9 companies compared; the peer median is $205.25M.
  • Its year-over-year change of -10.9% is the 7th highest of 9, against a peer median of -3.2%.
  • Research & development amounts to 36.0% of revenue for TXG, versus a peer median of 9.7%.
TXG Competitors Peer median
Research & Development for TXG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ILMNIllumina, Inc.LTM Jun 2026$958M -3.4%-10.4%21.3%
AAgilent Technologies, Inc.LTM Jul 2026$485M +8.5%-0.9%6.6%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$261.1M -14.3%+0.0%10.1%
TXG10x Genomics, Inc.LTM Sep 2026$222.54M -10.9%-3.5%36.0%
RVTYRevvity, Inc.LTM Jul 2026$215.83M +5.2%-0.9%7.4%
QGENQiagen N.V.LTM Jun 2026$194.67M +5.5%-0.4%9.3%
TECHBio-Techne CorporationLTM Sep 2026$96.87M -3.0%+0.8%7.9%
TWSTTwist Bioscience CorporationLTM Sep 2026$71.84M -10.5%-12.4%15.6%
LABStandard BioTools Inc.LTM Mar 2026$22.48M -43.6%-11.4%26.1%
Peer median (excluding TXG) $205.25M-3.2%-0.9%9.7%

Competitors are the stored peer set for TXG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue490.49M516.41M618.73M610.79M642.82M
Cost of Revenue74.09M120.39M209.41M196.3M198.94M
Gross Profit416.4M396.02M409.31M414.48M443.88M
Gross Margin84.9%76.7%66.2%67.9%69.1%
Research & Development211.75M265.67M270.33M264.7M238.63M
Selling, General & Admin257.56M298.3M343.33M344.34M316.13M
Operating Expenses469.31M563.97M674.64M609.04M554.77M
Depreciation & Amortization28.25M33.01M43.62M43.71M43.82M
EBITDA(24.6M)(128.49M)(205.11M)(133.99M)3.91M
EBITDA Margin-5.0%-24.9%-33.2%-21.9%0.6%
Operating Income(52.91M)(167.94M)(265.33M)(194.56M)(110.89M)
Operating Margin-10.8%-32.5%-42.9%-31.9%-17.2%
Interest Income206K6.65M16.91M18.45M20.05M
Interest Expense866K476K33K4K0
Other Income / Expenses(802K)5.97M16.57M16.86M70.98M
Income Before Tax(53.72M)(161.97M)(248.76M)(177.7M)(39.91M)
Pre-Tax Margin-11.0%-31.4%-40.2%-29.1%-6.2%
Income Tax Expense4.51M4.03M6.34M4.93M3.64M
Net Income(58.22M)(166M)(255.1M)(182.63M)(43.54M)
Net Margin-11.9%-32.1%-41.2%-29.9%-6.8%
EPS (Basic)(0.53)(1.46)(2.18)(1.52)(0.35)
EPS (Diluted)(0.53)(1.46)(2.18)(1.52)(0.35)
Weighted Avg Shares110.35M113.86M117.17M120.45M124.75M
Weighted Avg Shares (Diluted)110.35M113.86M117.17M120.45M124.75M

10x Genomics, Inc.

NASDAQ:TXG

Intrinsic Alpha fair value

Locked

Current Price

$57.07

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.